Expres2ion Biotech Holding Ab · OMXSTO:EXPRS2
Expres2ion Biotech Holding Ab — Virtual Oncology Webinar hosted by H.C. Andersen Capital (May 2022)
12 slides from Expres2ion Biotech Holding Ab's conference presentation, May 31, 2022
Slide 1: Proteins for Life – Virtual Oncology Webinar
31st May 2022 Proteins for Life Virtual Oncology Webinar Keith Alexander, CFO Mette Thorn, PhD, VP Preclinical Development
Slide 2: Disclaimer
Disclaimer This company presentation (the ”Company Presentation”), which is personal to the recipient, is issued by ExpreS2ion Biotech Holding AB (the “Company”). The Company Presentation has been prepared for information purposes only and is not to be relied upon in substitution for the exercise of
Slide 3: Investment Highlights
Investment Highlights Key player in advanced protein sciences, with deep pipeline of novel vaccines addressing high- value markets High-potential pipeline of key focus, backed up by Contract Research Organization (CRO) business, that has generated SEK 60 million since IPO in 2016 Vaccine development
Slide 4: Financials as of March 31, 2022 – Fitting the New Strategy
Financials as of March 31, 2022 – Fitting the New Strategy Cash, including the company’s Revenues, SEK ‘000s Operating costs, SEK ‘000s SKAT balance1, SEK million 6,000 1Q19 2Q19 3Q19 4Q19 1Q20 2Q203Q204Q20 1Q21 2Q21 3Q21 4Q21 1Q22 160 0 140 5,000 -3,000 120 4,000 -6,000 100 3,000 80 -9,000 60 2,000
Slide 5: Deep Pipeline for Value Creation
Deep Pipeline for Value Creation Development Progress Pre-clinical DISEASE Project/Target Discovery cGMP / Tox Phase I Phase II Phase III Partner/Funding Pharmacology Near term Phase III Coronavirus ABNCoV2/SARS-CoV-2cVLP ABNCoV2/SARS-CoV-2 cVLP I / II initiation: value H1 2022 PREVENT-nCoV Phase I
Slide 6: Our Technology & Oncology Program
Our Technology & Oncology Program Proteins for Life
Slide 7: Technology Platforms
Technology Platforms ExpreS2ion’s ExpreS2 and AdaptVac’s cVLP are our COVID-19 and Cancer vaccine technologies Particle (VLP) technology AdaptVac’s proprietary virus-like particles (VLP) technology Cell line derived from Drosophila melanogaster securely attaches our proteins to (fruit fly) S2 cells1
Slide 8: Breast Cancer Overview
BREAST CANCER Breast Cancer Overview The ES2B-C001 vaccine can offer significant benefits compared to current treatment options Monoclonal antibodies are the cornerstone of treatment Serious drawbacks exist with these therapies2 for HER2+ breast cancer (>USD 11bn sales)1 • Resistance to monoclonal a
Slide 9: ES2B-C001 Preclinical Proof-of-Concept (I)
BREAST CANCER ES2B-C001 Preclinical Proof-of-Concept (I) ES2B-C001 has demonstrated proof-of-concept Effectively inhibited tumor development in FVB mice Prevented tumor development in delta16 HER2 tg mice Tumor growth in FVB mice (HER2-intolerant) ES2B-C001 with adjuvant (n=20) Control (n = 10) Untr
Slide 10: ES2B-C001 Preclinical Proof-of-Concept (II)
BREAST CANCER ES2B-C001 Preclinical Proof-of-Concept (II) ES2B-C001 has demonstrated proof-of-concept Overcomes trastuzumab-resistance of tumors in vitro Inhibited tumor development in delta16 HER2 tg mice Trastuzumab-sensitive cells Trastuzumab-resistant cells Lung metastasis development in Delta 1
Slide 11: Advancing Towards Key Catalysts
BREAST CANCER Advancing Towards Key Catalysts 2022 2023 2024 BREAST CANCER (ES2B-C001) On path for Executed Preclinical Preclinical animal GMP Preclinical Filing of clinical Initiation of first Outlicensing window value in-licensing (Feb animal studies proof-of-concept manufacturing safety studies s
Slide 12: Proteins for Life – Thank you!
Thank you! Contact: info@expreS2ionbio.com Proteins for Life